Immunocompromised travelers: Demographic characteristics, travel destinations, and pretravel health care from the u.s. global travepinet consortium

American Journal of Tropical Medicine and Hygiene

Volumn 93, Issue 5, 2015, Pages 1110-1116

  Schwartz, Brian S ^{a,b,c,d,e,f,g,h,i}   Rosen, Jessica ^{a,b,c,d,e,f,g,h,i}   Han, Pauline V ^{a,b,c,d,e,f,g,h,i}   Hynes, Noreen A ^{a,b,c,d,e,f,g,h,i}   Hagmann, Stefan H ^{a,b,c,d,e,f,g,h,i}   Rao, Sowmya R ^{a,b,c,d,e,f,g,h,i}   Jentes, Emily S ^{a,b,c,d,e,f,g,h,i}   Ryan, Edward T ^{a,b,c,d,e,f,g,h,i}   LaRocque, Regina C ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRONX LEBANON HOSPITAL CENTER   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; TUMOR NECROSIS FACTOR INHIBITOR; YELLOW FEVER VACCINE; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; CLINICAL PRACTICE; COMMERCIAL PHENOMENA; CONSULTATION; DEMOGRAPHY; EMPORIATRICS; FEMALE; GRAFT RECIPIENT; HEALTH CARE; HUMAN; HUMAN DEVELOPMENT; IMMUNE STATUS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PRIMARY MEDICAL CARE; TRAVEL; UNITED STATES; VACCINATION; YELLOW FEVER; COMMUNICABLE DISEASE CONTROL; COUNSELING; HEALTH CARE DELIVERY; IMMUNOLOGY; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; COUNSELING; DELIVERY OF HEALTH CARE; DEMOGRAPHY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MIDDLE AGED; TRAVEL; UNITED STATES; YOUNG ADULT;

EID: 84946746150     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.15-0185     Document Type: Article

References (31)

1. International Trade Administration. 2013 U. S. Travel and Tourism Statistics. Office of Travel and Tourism Industries, U. S. Department of Commerce. Available at: http://tinet. ita. doc. gov/ outreachpages/outbound. general-information . outbound-overview. html. Accessed March 4, 2011.
2. United Nations World Tourism Organization. Press Release No. PR120020, January 2012. Available at: http://media. unwto . org/en/press-release/2012-01-16/international-tourism-reach-onebillion-2012. Accessed March 5, 2012.
3. Organ Procurement and Transplantation Network. U. S. transplants performed January-March 2014. Available at: http:// optn. transplant. hrsa. gov/data/. Accessed June 24, 2014.
4. Chen M, Rhodes PH, Hall IH, Kilmarx PH, Branson BM, Valleroy LA, Centers for Disease Control and Prevention (CDC), 2012. Prevalence of undiagnosed HIV infection among persons aged ? 13 years-national HIV surveillance system, United States, 2005-2008. Morb Mortal Wkly Rep 61 (Suppl): 57-64.
5. Uslan DZ, Patel R, Virk A, 2008. International travel and exposure risks in solid-organ transplant recipients. Transplantation 86: 407-412.
6. Kemper CA, Linett A, Kane C, Deresinski SC, 1995. Frequency of travel of adults infected with HIV. J Travel Med 2: 85-88.
7. Kemper CA, Linett A, Kane C, Deresinski SC, 1997. Travels with HIV: the compliance and health of HIV-infected adults who travel. Int J STD AIDS 8: 44-49.
8. Salit IE, Sano M, Boggild AK, Kain KC, 2005. Travel patterns and risk behaviour of HIV-positive people travelling internationally. CMAJ 172: 884-888.
9. 2011. CDC Health Information for International Travel 2012. Atlanta, GA: U. S. Department of Health and Human Services, Public Health Service.
10. Roukens AH, van Dissel JT, de Fijter JW, Visser LG, 2007. Health preparations and travel-related morbidity of kidney transplant recipients traveling to developing countries. Clin Transplant 21: 567-570.
11. Wieten RW, Leenstra T, Goorhuis A, van Vugt M, Grobusch MP, 2012. Health risks of travelers with medical conditions-a retrospective analysis. J Travel Med 19: 104-110.
12. LaRocque RC, Rao SR, Lee J, Ansdell V, Yates JA, Schwartz BS, Knouse M, Cahill J, HAgmann S, Vinetz J, Connor BA, Goad JA, Oladele A, Alvarez S, Stauffer W, Walker P, Kozarsky P, Franco-Paredes C, Dismukes R, Rosen J, Hynes NA, Jacquerioz F, McLellan S, Hale D, Sofarelli T, Schoenfeld D, Marano N, Brunette G, Jentes ES, Yanni E, Sotir MJ, Ryan ET;Global Travel Epinet Consortium, 2012. Global TravEpiNet: a national consortium of clinics providing care to international travelers-analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect Dis 54: 455-462.
13. United Nations Development Programme. Human Development Report, 2011. Available at: http://hdr. undp. org/en/content/humandevelopment-report-2011.
14. Rao SR, LaRocque RC, Jentes ES, Hagmann SHF, Ryan ET, Han PV, Kleinbaum DG, 2014. Comparison of methods for clustered data analysis in a non-ideal situation: results from an evaluation of predictors of yellow fever vaccine refusal in the Global TravEpiNet (GTEN) consortium. Int J Stat Med Res 3: 215-223.
15. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM, 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 345: 1098-1104.
16. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM; Infectious Diseases Society of America Emerging Infections Network, 2008. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis 46: 1738-1740.
17. Zanger P, Kotter I, Kremsner PG, Gabrysch S, 2012. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect 18: 670-676.
18. Pena-Sagredo JL, Farinas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibanez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernandez MV, Rodriguez-Gomez M, Maiz O, Lopez R, Cobo T, Pita J, Carmona L, Gonzales-Gay MA; BIOBADASER and EMECAR Groups, 2009. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy. Clin Exp Rheumatol 27: 920-925.
19. Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podesta E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Lagana B, D Amelio R, 2010. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 134: 113-120.
20. Kaine JL, Kivitz AJ, Birbara C, Luo AY, 2007. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 34: 272-279.
21. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I; Infectious Diseases Society of America, 2014. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58: e44-e100.
22. Orenstein R, 2005. Travel in patients receiving TNF-alpha inhibitors. Travel Med Infect Dis 3: 105-109.
23. Curtis DJ, Muresan P, Nachman S, Fenton T, Richardson KM, Dominguez T, Flynn PM, Spector SA, Cunningham CK, Bloom A, Weinberg A, 2015. Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth. PLoS One 10: e0118567.
24. Berger CT, Greiff V, Mehling M, Fritz S, Meier MA, Hoenger G, Conen A, Recher M, Battegay M, Reddy ST, Hess C, 2015. Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection. Hum Vaccin Immunother 11: 391-396.
25. George VK, Pallikkuth S, Parmigiani A, Alcaide M, Fischl M, Arheart KL, Pahwa S, 2015. HIV infection worsens ageassociated defects in antibody responses to influenza vaccine. J Infect Dis 211: 1959-1968.
26. Centers for Disease Control and Prevention (CDC), 2013. Prevention and control of seasonal influenza with vaccines. recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Recomm Rep 62: 1-43.
27. LaRocque RC, Jentes ES, 2011. Health recommendations for international travel: a review of the evidence base of travel medicine. Curr Opin Infect Dis 24: 403-409.
28. Mauskopf J, Klesse M, Lee S, Herrera-Taracena G, 2013. The burden of influenza complications in different high-risk groups: a targeted literature review. J Med Econ 16: 264-277.
29. Centers for Disease Control and Prevention (CDC), 2005. Cruise-ship-associated Legionnaires disease, November 2003-May 2004. Morb Mortal Wkly Rep 54: 1153-1155.
30. Wikswo ME, Cortes J, Hall AJ, Vaughan G, Howard C, Gregoricus N, Cramer EH, 2011. Disease transmission and passenger behaviors during a high morbidity norovirus outbreak on a cruise ship, January 2009. Clin Infect Dis 52: 1116-1122.
31. Miller JM, Tam TW, Maloney S, Fukuda K, Cox N, Hockin J, Kertesz D, Klimov A, Cetron M, 2000. Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect Dis 31: 433-438.